Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ocriplasmin Research to Better Inform Treatment (ORBIT)

NCT02079883 is registered in ClinicalTrials.gov with ThromboGenics as lead sponsor.

NCT NCT02079883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02079883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ocriplasmin Research to Better Inform Treatment (ORBIT)
Lead sponsor
ThromboGenics
Phase
Observational
Overall status
Completed
Start date
May 31, 2014
Completion date
May 31, 2016
Enrollment
540 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic vitreomacular adhesion